Dr Peter A McCullough was born in Buffalo, New York, on the 29th of December 1962. During high school, he and his family moved to Wichita Falls in Texas and later settled in Grapevine. He has lived and worked in various parts of the United States, including Washington and Michigan, and he now resides in Dallas, Texas. Academic History Dr McCullough attended Baylor University and graduated with a Bachelor of Science degree in 1984. He then attended the University of Texas Southwestern Medical Center, where he studied for his medical degree and graduated in June 1988. Following this, he undertook his residency in internal medicine at the University of Washington School of Medicine in Seattle, where he trained for 3 years.Upon completing his residency in 1991, Dr McCullough transferred to Grayling, Michigan, where he served for 2 years as an internal medicine attending at Mercy Hospital. Following his time at Mercy Hospital, he enrolled at the University of Michigan School of Public Health and studied a Masters degree in Public Health. After he graduated from the University of Michigan School of Public Health in 1994, he became a fellow in cardiovascular diseases at the Beaumont Hospital in Royal Oak, Michigan.

Thomas J. Webster’s (H index: 138) degrees are in chemical engineering from the University of Pittsburgh (B.S., 1995; USA) and in biomedical engineering from RPI (Ph.D., 2000; USA). He has formed over a dozen companies who have numerous FDA approved medical products currently improving human health in over 45,000 patients. He is currently helping those companies and serves as a professor at Brown University, Saveetha University, Hebei University of Technology, UFPI, University of the Basque Country, and others. Dr. Webster has numerous awards including: 2020, World Top 2% Scientist by Citations (PLOS); 2020, SCOPUS Highly Cited Research (Top 1% Materials Science and Mixed Fields); 2021, Clarivate Top 0.1% Most Influential Researchers (Pharmacology and Toxicology); 2022, Best Materials Science Scientist by Citations (Research.com); and is a fellow of over 8 societies. Prof. Webster is a former President of the U.S. Society for Biomaterials and has over 1,350 publications to his credit with over 55,000 citations. He was recently nominated for the Nobel Prize in Chemistry. Prof. Webster also recently formed a fund to support Nigerian student research opportunities in the U.S.

Dr. Pascal J. Goldschmidt-Clermont is a distinguished cardiologist, physician executive, scientist, and health system leader whose career spans more than four decades of transformative leadership in academic medicine, healthcare innovation, and corporate governance. He currently serves as Chief Medical Officer of Lennar Corporation, one of the nation's leading homebuilders, where he champions preventive health strategies and workforce wellness initiatives. He is the founder of the Healthiest Company in America (HCIA) journey, an evidence-based program focused on age- and risk-appropriate screening, disease prevention, and population health improvement. Dr. Goldschmidt-Clermont is Dean Emeritus and Professor of Medicine Emeritus at the University of Miami Miller School of Medicine. From 2006 to 2016, he served as Senior Vice President for Medical Affairs and Dean, leading the institution through a period of unprecedented growth and innovation. He founded and served as Chief Executive Officer of UHealth, the University of Miami Health System, establishing one of the nation's premier integrated academic health systems. Prior to Miami, Dr. Goldschmidt-Clermont held leadership positions at the Duke University School of Medicine, The Ohio State University College of Medicine, and Johns Hopkins University School of Medicine, where he directed major cardiovascular research and clinical programs while mentoring generations of physicians and scientists. An internationally recognized investigator, Dr. Goldschmidt-Clermont has authored more than 250 scientific publications and holds multiple patents. His research has advanced understanding in cardiovascular genetics, vascular biology, oxidative stress, cytoskeletal signaling, progenitor cell biology, atherosclerosis, and novel approaches to opioid withdrawal therapy. His work has been supported by significant funding from the National Institutes of Health (NIH) and other leading research organizations. Beyond academia, he has served on numerous public and private company boards and healthcare organizations, including MEDNAX, OPKO Health, Health Management Associates, Demerx, NeoBiosis, ComKardia, United HomeCare, Jackson Health System, and the University of Miami. His expertise spans healthcare delivery, life sciences, biotechnology, corporate governance, and strategic innovation. Dr. Goldschmidt-Clermont's contributions have been recognized with numerous honors, including the Schottenstein Prize in Cardiovascular Sciences, election as Fellow of the American College of Cardiology (FACC) and Fellow of the American Heart Association (FAHA), membership in the Johns Hopkins Society of Scholars, and repeated selection among Best Doctors in America. Born in Brussels, Belgium, and a naturalized United States citizen, Dr. Goldschmidt-Clermont is widely respected for his visionary leadership, scientific excellence, commitment to public health, and enduring legacy of mentorship. His career reflects a unique ability to bridge medicine, research, education, and business to improve health outcomes on a global scale. web domain: pascalgoldschmidtclermont.squarespace.com

Dr. Fujiwara is Professor of the Department of Public Health and Director General of the Institute of Future Science at the Institute of Science Tokyo. His research interests include child health and development, social epidemiology, life-course epidemiology, and climate change and health. He also serves as Director of the Master of Public Health Program at the Institute of Science Tokyo. He graduated from the Faculty of Medicine and Graduate School at Tokyo Medical and Dental University (MD, 2000; PhD, 2004) and the Harvard T.H. Chan School of Public Health (MPH, 2006). He has published more than 500 peer-reviewed papers and his H-index is approximately 60.

Prof. AR Thierry began his career focusing on gene therapy solutions and DNA auto-organization complex formation. Since the early 2000s, he has made significant contributions to the research and applications of circulating DNA (cirDNA), particularly in oncology. He coordinated the first prospective blinded multicenter studies to achieve clinical validation of plasma analysis for detecting mutations in oncology and demonstrated the clinical benefits of cirDNA analysis in digestive oncology. His research also explores other potentials of cirDNA, in cancer care. He introduced the first guidelines for cirDNA pre-analytical conditions to the scientific community. His team has been dedicated to fundamental research on cirDNA structure and functions, pioneering studies on cirDNA fragmentation and suggesting potential solutions for cancer screening using fragmentomics. They discovered circulating functional cell-free mitochondria in blood and recently linked cirDNA with NETs production in cancer, COVID-19, and long COVID as well as with circulating microclots. Prof. AR Thierry is now developing tools for cancer screening, and diagnosing inflammatory diseases and viral infections.

Mark Feitelson received his Ph.D. in Microbiology and Immunology in 1979 from UCLA. He was an American Cancer Society postdoctoral fellow at Stanford University from 1979-82 and was then recruited to the Fox Chase Cancer Center by Dr. Baruch Blumberg (Nobel laureate). He has since worked on the pathogenesis of hepatitis B and development of hepatocellular carcinoma on the cell and molecular levels. In 1991, Dr. Feitelson moved to Thomas Jefferson University where he became Professor of Pathology and Cell Biology. He also was director of a Molecular Diagnostics Lab in Microbiology. In 2007, Dr. Feitelson went to Temple University as a Professor of Biology. His work has been supported by NIH, industry and foundations, has more than 150 publications, and 180 abstracts. He was also the founding director of the Professional Science Master’s program in Biotechnology at Temple University. He is currently CSO of SFA Therapeutics, which is a Temple University spin-out of work from his lab. SFA has won many awards for innovation and excellence and is currently in human clinical trials for gut microbiome-based treatments for autoimmune diseases and cancer. Dr. Feitelson has 17 patents and has been a consultant for more than 10 companies since the 1980s. Dr. Feitelson has also been active in teaching undergraduate and graduate courses including microbiology, virology, and critical thinking in biology (undergraduate), overseeing Biology of Cancer (undergraduate) and microbial biotechnology (graduate). In the lab, he has mentored over 130 students since the mid-1980s, including 24 master’s students in Biology, 8 Ph.D. students in Biology, and 13 postdoctoral fellows.